CA-NEXON-AMERICA-INC
14.5.2020 05:02:10 CEST | Business Wire | Press release
The highly-anticipated free to play kart racing game, KartRider: Drift , will hold its second Closed Beta starting June 3, 2020 via the Nexon Launcher, Steam, and Xbox One, including Xbox One X delivering cross-platform play. Players can register here for a chance to join the second Closed Beta starting today!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005906/en/
Players invited to the second Closed Beta will receive an acceptance email, and they can pre-download the game starting on June 1, 2020 at 7 p.m. PDT. Players who participated in the first Closed Beta will automatically be included.
During the Closed Beta period, players will be introduced to a new character — Diz, as well as new skins for existing characters, plus additional karts and tracks. The Closed Beta will also showcase new functions such as Racing Pass and a new Racing School single-player mode, where new and experienced players can improve their racing skills.
Customization will be a huge part of this Closed Beta with the preview of the new wraps, which allows racers to paint their karts and create unique designs for maximum personalization. Participants will also have access to kart upgrades including choice of license plate and can decorate their karts with a lineup of new accessory balloons and character emotes.
Players will also see a revamped User Interface with a new HUD and contextual rear view mirror. The matchmaking experience has also been improved as players will be queued based on their performance in the tutorial. Driving physics of the game have also been improved since the first Closed Beta for a better racing experience.
To reward players who log in during the Closed Beta, special login rewards including a Turbo Tortoise Kart, Bunny Buggy Kart, Simian Scrapper Kart, and Deuce Coupe Kart will be unlocked. All Beta participants will also receive a White Cloud Balloon item at official launch.
Players who sign up for Closed Beta 2 at www.kartriderdrift.net will be in for a treat as KartRider: Drift has partnered with HyperX, ViewSonic and DXRacer, for an opportunity to win exclusive prizes.
KartRider: Drift’s Closed Beta will be available worldwide on the Nexon Launcher, Steam, Xbox One, including Xbox One X, with the exception of Japan, and China on console. To see a full list of available regions, please follow this link .
For more information on KartRider: Drift , visit www.kartriderdrift.net or follow @KartRiderDrift on Twitter for the latest updates and information on contests and giveaways.
Social Media: Facebook / Twitter / Instagram / Discord / Official Site
Press Assets:
About KartRider: Drift http://kartrider.nexon.net/
Launched in 2004, KartRider is a massively popular multiplayer racing franchise that boasts more than 300 million PC players. Making its debut to western audiences, KartRider: Drift takes inspiration from earlier iterations of the game, delivering competitive drift-fueled racing action, featuring different game modes, and deep character + kart customization. Available completely for free on PC Steam, Xbox One, including Xbox One X, and Nexon Launcher (PC), KartRider: Drift offers cross-platform capabilities to challenge friends regardless of the platform they choose or where they are in the world.
About Nexon America Inc. http://www.nexon.net/corporate/about-nexon/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005906/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom